The company registered a RON10.8 million net loss, from RON17.4 million profit in H1/2024, mainly due to currency fluctuations.
The group posted RON1.49 billion operating expenses in H1/2025, up 21.1% from the year-earlier period.
Operating profit increased by 7.5% for the 6-month period of 2025 compared to the same period of 2024, from RON 78,436,028 in 2024 to RON 84,307,467 in 2025.
Most business lines of the group registered a good performance against the same period of last year.
In addition to solid financial results, MedLife has accelerated strategic investments in genetics and artificial intelligence, two directions that will fundamentally transform the medicine of the future. Thus, in the first half of the year, the company invested EUR 3 million in the acquisition of Illumina NovaSeq X Plus, the most advanced sequencing technology in the world, preparing the launch of a large-scale genetic testing program. The initiative aims to democratize genetic testing in Romania and move to a proactive approach to medicine, based on accurate data and prevention.
At the same time, the Group has taken important steps in integrating artificial intelligence solutions in imaging and laboratory, introducing new facilities that support both the accuracy of the medical act and the personalized response to patients’ needs.
„Genetics and artificial intelligence will transform the medicine of the future, and MedLife aims to be at the forefront of this change. We will launch several revolutionary products in the immediate future, at least for the Romanian market. Consequently, we aim to democratize genetics at the subscriber level and beyond, and to provide them with information about the risks associated with each person at a level never seen before. Thus, through strategic investments and innovative genetic testing programs, we open a new chapter for the Romanian medical system and bring personalized medicine closer to patients. In parallel, the development and integration of our own Romanian AI solutions into operational processes, the corroboration of medical data and their personalized interpretation will allow us to place a much greater emphasis on preventive medicine and directly contribute to increasing the quality of life of Romanians, for a healthier and, why not, longer life”, said Mihai Marcu, President and CEO MedLife Group.
MedLife has a RON4 billion capitalization, after its shares have added 43% since the start of the year amid deals worth RON182 million.
(English version by Catalina Apostoiu)